nevirapine has been researched along with Birth Weight in 3 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
Birth Weight: The mass or quantity of heaviness of an individual at BIRTH. It is expressed by units of pounds or kilograms.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bhattacharya, D | 1 |
| Guo, R | 1 |
| Tseng, CH | 1 |
| Emel, L | 1 |
| Sun, R | 1 |
| Chiu, SH | 1 |
| Stranix-Chibanda, L | 1 |
| Chipato, T | 1 |
| Mohtashemi, NZ | 1 |
| Kintu, K | 1 |
| Manji, KP | 1 |
| Moodley, D | 1 |
| Thio, CL | 1 |
| Maldonado, Y | 1 |
| Currier, JS | 1 |
| Charurat, M | 1 |
| Datong, P | 1 |
| Matawal, B | 1 |
| Ajene, A | 1 |
| Blattner, W | 1 |
| Abimiku, A | 1 |
| Ivanovic, J | 1 |
| Nicastri, E | 1 |
| Anceschi, MM | 1 |
| Ascenzi, P | 1 |
| Signore, F | 1 |
| Pisani, G | 1 |
| Vallone, C | 1 |
| Mattia, E | 1 |
| Notari, S | 1 |
| Tempestilli, M | 1 |
| Pucillo, LP | 1 |
| Narciso, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
| Intervention | Number of Adverse Events (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-Threatening | Severe | Moderate | Mild | |
| Nevirapine | 26 | 87 | 375 | 694 | 832 |
| Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
| Intervention | participants (Number) | |
|---|---|---|
| # of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
| Nevirapine | 8 | 700 |
| Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
| Nevirapine | 26 | 678 |
| Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
| Intervention | participants (Number) | |
|---|---|---|
| Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
| Nevirapine | 689 | 629 |
| Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
| Nevirapine | 16 | 664 |
| Placebo | 23 | 663 |
2 trials available for nevirapine and Birth Weight
| Article | Year |
|---|---|
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi | 2021 |
Timing and determinants of mother-to-child transmission of HIV in Nigeria.
Topics: Adult; Anti-HIV Agents; Birth Weight; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hum | 2009 |
1 other study available for nevirapine and Birth Weight
| Article | Year |
|---|---|
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birt | 2009 |